Literature DB >> 2649867

A multicenter therapeutic study of 1100 children with brucellosis.

M M Lubani1, K I Dudin, D C Sharda, D S Ndhar, G F Araj, H A Hafez, Q A al-Saleh, I Helin, M M Salhi.   

Abstract

A 6-year multicenter therapeutic study was performed on 1100 children with brucellosis in order to compare several antibiotic combinations and duration of treatment. The patients were randomized to receive oral therapy with oxytetracycline, doxycycline, rifampin and trimethoprim-sulfamethoxazole (TMP/SMX) either alone or in combination with each other or combined with streptomycin or gentamicin injections. The patients were also randomized into three groups based on the duration of oral therapy: 500 patients were treated for 3 weeks; 350 for 5 weeks; and 250 for 8 weeks. When intramuscular aminoglycosides were used, streptomycin was given for 2 weeks and gentamicin for 5 days. In oral monotherapy oxytetracycline, doxycycline and rifampin showed comparable results with low relapse rates (less than or equal to 9%) and no statistically significant differences were found among 3-, 5- or 8-week durations of therapy. TMP/SMX alone showed an unacceptably high relapse rate (30%) with all durations of therapy. In combined oral therapy rifampin plus oxytetracycline, rifampin plus TMP/SMX and oxytetracycline plus TMP/SMX showed comparable results with low relapse rates ranging from 4 to 8% in patients receiving therapy for 3 or 5 weeks, no relapses occurred in patients treated for 8 weeks. When oral monotherapy was combined with either streptomycin or gentamicin, very few relapses were seen, irrespective of the duration of treatment.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2649867

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  15 in total

1.  Hydrophobic gentamicin-loaded nanoparticles are effective against Brucella melitensis infection in mice.

Authors:  Edurne Imbuluzqueta; Carlos Gamazo; Hugo Lana; Miguel Ángel Campanero; David Salas; Ana Gloria Gil; Elisa Elizondo; Nora Ventosa; Jaume Veciana; María J Blanco-Prieto
Journal:  Antimicrob Agents Chemother       Date:  2013-05-06       Impact factor: 5.191

Review 2.  Optimum treatment of intracellular infection.

Authors:  M Maurin; D Raoult
Journal:  Drugs       Date:  1996-07       Impact factor: 9.546

3.  A case of acute septic arthritis hip caused by Brucella melitensis in an adolescent child.

Authors:  Divesh Jalan; Abhay Elhence; Poonam Elhence; Princi Jain
Journal:  BMJ Case Rep       Date:  2015-09-21

Review 4.  The current therapeutical strategies in human brucellosis.

Authors:  Mile Bosilkovski; Fariba Keramat; Jurica Arapović
Journal:  Infection       Date:  2021-03-01       Impact factor: 3.553

5.  Treatment of human brucellosis with doxycycline and gentamicin.

Authors:  J Solera; A Espinosa; E Martínez-Alfaro; L Sánchez; P Geijo; E Navarro; J Escribano; J A Fernández
Journal:  Antimicrob Agents Chemother       Date:  1997-01       Impact factor: 5.191

6.  Childhood brucellosis in north-western Greece: a retrospective analysis.

Authors:  E Galanakis; K L Bourantas; S Leveidiotou; P D Lapatsanis
Journal:  Eur J Pediatr       Date:  1996-01       Impact factor: 3.183

Review 7.  Recognition and optimum treatment of brucellosis.

Authors:  J Solera; E Martínez-Alfaro; A Espinosa
Journal:  Drugs       Date:  1997-02       Impact factor: 9.546

8.  Pediatric anthrax clinical management.

Authors:  John S Bradley; Georgina Peacock; Steven E Krug; William A Bower; Amanda C Cohn; Dana Meaney-Delman; Andrew T Pavia
Journal:  Pediatrics       Date:  2014-05       Impact factor: 7.124

9.  Doxycycline-rifampin versus doxycycline-streptomycin in treatment of human brucellosis due to Brucella melitensis. The GECMEI Group. Grupo de Estudio de Castilla-la Mancha de Enfermedades Infecciosas.

Authors:  J Solera; M Rodríguez-Zapata; P Geijo; J Largo; J Paulino; L Sáez; E Martínez-Alfaro; L Sánchez; M A Sepulveda; M D Ruiz-Ribó
Journal:  Antimicrob Agents Chemother       Date:  1995-09       Impact factor: 5.191

10.  Neurobrucellosis in children.

Authors:  M H Estevão; L M Barosa; L M Matos; A A Barroso; H C da Mota
Journal:  Eur J Pediatr       Date:  1995-02       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.